Vanilloid Receptor TRPV1 in Drug Discovery: Targeting Pain and Other Pathological Disorders

ISBN-13: 9780470175576 / Angielski / Twarda / 2010 / 480 str.

¬Abar;¬Abar

Opis

Examines the emerging therapeutic role of TRPV1 TRPV1 is considered an integrator of noxious stimuli and therefore may be at a crossroads for pain transmission pathways. Because of its potential for managing multiple pain types, including osteoarthritis, chronic low back pain, neuropathic pain, and cancer pain, some consider it "the holy grail" of pain management. This dedicated reference summarizes available data related to the potential therapeutic utility for TRPV1 ligands. With contributions from many of the world's leading experts on TRP channels, Vanilloid Receptor TRPV1 in Drug Discovery covers the important TRPV1 target for drugs to treat painful conditions such as inflammation, arthritis, and cancer pain. The book discusses:

• Recent advances in biology, chemistry, and pharmacology at both the preclinical and clinical stage of the dynamic area of TRPV1 drug discovery research
• The potential for drugs targeting TRPV1 in painful conditions such as inflammation, arthritis, and cancer
• The development of analgesic drugs
• Other applications for TRPV1, including the treatment of respiratory disease and diabetes

Featuring data relevant to the therapeutic potential of TRPV1 and the medicinal chemistry involved in designing TRPV1 antagonists, Vanilloid Receptor TRPV1 in Drug Discovery is a key tool for researchers in the pharmaceutical industry and academia involved in pain, ion channels, and analgesic drug development.

Spis treści

Preface and Acknowledgments.

Foreword.

Contributors.

PART I INTRODUCTION TO THE TRP CHANNELS.

1 TRP Channels and Human Diseases (Bernd Nilius and Rudi Vennekens).

2 Role of TRP Channels in Pain: An Overview (Arpad Szallasi).

3 Biochemical Pharmacology of TRPV1: Molecular Integrator of Pain Signals (Carol S. Surowy, Philip R. Kym, and Regina M. Reilly).

4 TRPV1 Genetics (Ruslan Dorfman, Hubert Tsui, Michael W. Salter, and H.–Michael Dosch).

PART II ROLE FOR TRPV1 IN PAIN STATES.

5 TRPV1 and Inflammatory Pain (Anindya Bhattacharya, Sonya G. Lehto, and Narender R. Gavva).

6 Role of TRPV1 Receptors in Osteoarthritic Pain (Shailen K. Joshi and Prisca Honore).

7 TRPV1 and Bone Cancer Pain (Juan Miguel Jimenez–Andrade and Patrick Mantyh).

8 TRPV1 in Visceral Pain and Other Visceral Disorders (António Avelino and Francisco Cruz).

9 TRPV1 Receptors and Migraine (Philip R. Holland and Peter J. Goadsby).

10 TRPV1 in Neuropathic Pain and Neurological and Neuropsychiatric Disorders (Enza Palazzo, Katarzyna Starowicz, Sabatino Maione, and Vincenzo Di Marzo).

PART III TRPV1 ANTAGONISTS AND AGONISTS AS NOVEL ANALGESIC DRUGS.

11 Aryl–Urea Class and Related TRPV1 Antagonists (Arthur Gomtsyan).

12 2–Pyridinylpiperazine Carboxamide Class and Related TRPV1 Antagonists (Natalie A. Hawryluk and Nicholas I. Carruthers).

13 TRPV1 Agonist Approaches for Pain Management (Keith R. Bley).

PART IV ROLE FOR TRPV1 IN OTHER PHYSIOLOGICAL PROCESSES BESIDES PAIN TRANSMISSION.

14 The TRPV1 Channel in Normal Thermoregulation: What Have We Learned from Experiments Using Different Tools? (Andras Garami, Maria C. Almeida, Tatiane B. Nucci, Tamara Hew–Butler, Renato N. Soriano, Eszter Pakai, Kazuhiro Nakamura, Shaun F. Morrison, and Andrej A. Romanovsky).

15 The Role of TRPV1 in Respiratory Diseases (Serena Materazzi, Alain Tchoimou, Romina Nassini, Marcello Trevisani, and Pierangelo Geppetti).

16 The Role of TRPV1 in Diabetes (Hubert Tsui, Ruslan Dorfman, Michael W. Salter, and H.–Michael Dosch).

Afterword.

Index.

O autorze

ARTHUR GOMTSYAN is an Associate Research Fellow at Abbott Laboratories where he focuses on neuroscience research and pain drug targets. He is on the editorial board of two peer–reviewed journals and has over forty scientific articles to his credit.

CONNIE R. FALTYNEK is a Director for Neuroscience and Pain Discovery at Abbott Laboratories. She has twenty years′ experience in drug discovery research in the pharmaceutical industry and has published nearly 100 scientific papers.